Summit Therapeutics Inc. (SMMT)
Free
No email, no account, no signup.
Pulling latest news for Summit Therapeutics Inc.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Oncology drug development
Market Cap
$13.6B
We're already tracking Summit Therapeutics Inc. — here are the latest events we've registered
Recent News
- On May 1, 2026, Summit reported that an interim analysis of its Phase III HARMONi-3 trial for ivonescimab in lung cancer did not reach statistical significance, though the study will continue to its final readout in late 2026. The company also reported Q1 2026 financial results, showing a cash position of approximately $598.7 million and a net loss of $189.4 million. Shares fell significantly following the clinical update and the disclosure of a going-concern risk.
Want to know how this news affects Summit Therapeutics Inc.? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Summit Therapeutics Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.